In a welcome move, Establishment Labs Hldgs saw its Relative Strength Rating rise from 65 to 77 on Tuesday.
Can You Really Time The Stock Market?
IBD's unique rating identifies price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they launch their biggest climbs. See if Establishment Labs Hldgs can continue to rebound and hit that benchmark.
Establishment Labs Hldgs is not currently near a potential buy zone. See if the stock goes on to build a promising consolidation that could spark a new run.
Establishment Labs Hldgs showed 0% earnings growth in the latest quarterly report. Revenue rose 11%.
Establishment Labs Hldgs earns the No. 44 rank among its peers in the Medical-Products industry group. Boston Scientific, Insulet and ResMed are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
